PISCATAWAY, N.J., Oct. 20, 2025 /PRNewswire/ — London will become the global spotlight for cell and gene therapy (CGT) this November as Nobel Laureate, scientific leaders, biotech innovators, and top investors convene to chart the future of one of the fastest-growing fields in emerging medicine.

CGT is rapidly transforming the landscape of modern medicine, driving breakthroughs from laboratory research into real-world clinical applications. From genome editing to in vivo and ex vivo cell therapy platforms, CGT has become one of the most promising fields in life sciences, supported by rising global investment and innovation.

To explore the opportunities and challenges of this rapidly evolving field, the GenScript Biotech Global Forum London 2025 will be held on November 20, 2025, in London, United Kingdom, in conjunction with the Jefferies London Healthcare Conference. Under the theme “THE NEXT ERA OF CGT IS HERE,” the forum will explore how these innovations can be translated into sustainable, real-world patient impact.

RSVP: http://bit.ly/467jaet
(Register with code GSGM3 to claim a complimentary ticket — limited to the first 20 registrants)

Craig Mello, Carl June, and Miguel Forte to Lead Keynotes

A highlight of the event will be keynote speeches by leading figures in the field:

Dr. Craig Mello, Nobel Laureate in Physiology or Medicine (2006), University Chair in Molecular Medicine, co-director of the RNA Therapeutics Institute at the University of Massachusetts Medical School, is best known for his co-discovery of RNA interference (RNAi), a breakthrough that transformed genetic research and paved the way for RNA-based medicines. On the topic of “RNAi: A Molecular Spark in an Information Inferno,” Dr. Mello will reflect on how foundational science has evolved into real-world therapeutic innovation and what lessons this holds for the next generation of CGT.

Dr. Carl June is the Richard W. Vague Professor in Immunotherapy and Director of the Center for Cellular Immunotherapies at the University of Pennsylvania. His pioneering work led to the first FDA-approved CAR-T therapy, ushering in a new era of cancer treatment. Dr. June will deliver his remarks via a video presentation highlighting recent clinical advances in cellular immunotherapies and share his insights on future directions. 

Dr. Miguel Forte, President and Board of Directors Chair of the International Society for Cell & Gene Therapy (ISCT), brings deep expertise in clinical development and regulatory strategy. He will offer a global perspective on clinical translation, manufacturing (CMC) challenges, and regulatory pathways that will shape the scalability and accessibility of CGT on the topic of “Crossing the Desert: Challenges and Reasons to Believe in Cell and Gene Therapy.“

Industry Leaders Charting New Frontiers

The forum will feature in-depth sessions on four core areas:

1^st Panel: Navigating the Future of Cell Therapy: Evaluating Varied Pathways in Cell Therapy Innovation for Comprehensive Sector Insights

Cell therapy is evolving rapidly across autologous, allogeneic, and in vivo platforms, each facing unique challenges in scalability, safety, and cost. This session will highlight key innovations—from solid tumor advances to AI-driven breakthroughs—shaping the future of cell therapy.

Panelists include:

• Ying Huang, CEO, Legend Biotech
• Paul Stoffels, Former CSO, Johnson & Johnson
• Paula Río, Head of the Bone Marrow Aplasia Unit, CIEMAT/CIBERER/IIS-FJD
• Marcello Maresca, Senior Director of Genome Engineering Department, AstraZeneca
• Jonathan Esensten, Senior Advisor, Multiply Labs

Moderator:

• Stephen Hansen, Director of Biopharma Intelligence, BioCentury

2^nd panel: Gene Therapy and mRNA Therapeutics

Explore how gene and mRNA therapies are translating promise into practice, tackling challenges in delivery, durability, and safety, and shaping the next wave of medical innovation.

Panelists include:

• Sergio Linares, Unit Head of RNA Science Automation, Sanofi
• Luigi Calzolai, Scientific Officer, European Commission Joint Research Centre (JRC)
• Anna Cereseto, Head of Lab for Advanced Genome Editing Technologies, University of Trento
• Robin Shattock, Chair in Mucosal Infection and Immunity, Imperial College London
• Miroslav Gasparek, CEO and Co-founder, Sensible Biotechnologies

Moderator:

• Julen Oyarzabal, CSO, Syngoi Technologies SL

3^rd panel: From Lab to Patient: Overcoming CMC Barriers in Cell and Gene Therapy Manufacturing

Despite its promise, CGT faces manufacturing challenges, with CMC hurdles impacting reproducibility, scalability, and regulatory compliance. The session will examine strategies and solutions for overcoming these barriers in CGT manufacturing.

Panelists include:

• Jin Yin, CTO, CGT Technology Center, ProBio
• John Maher, Scientific Founder and CSO, Leucid Bio
• Marten Hansen, Head of the Laboratory for Cell Therapy, Sanquin Blood Supply Foundation
• Dima Al-hadithi, Founder and Director of Minaret Consulting Limited and RareGenix Consulting Limited

Moderator:

• Peter Jones, Director, Pengwin Consultancy

4^th panel: Innovation and Investment for CGT

The pace of scientific progress in CGT has been matched by strong interest from the investment community. Turning breakthroughs into sustainable business models requires a clear understanding of the risks and opportunities ahead. This session will explore strategies for aligning innovation with investment to drive long-term success in CGT.

Panelists include:

• Laura Stoppel, Partner on the Investment Team, RA Capital Management
• Hongbo Lu, Founder and Managing Partner, NextBio Capital
• Daniela Couto, General Partner, BioGeneration Ventures
• Michiel Broker, Managing Director and Global Head of Pharma, UBS
• Matthieu Coutet, Partner, Sofinnova Biovelocita Strategy

Moderator:

• Michael Brinkman, Managing Director and Joint US Head of Biopharmaceuticals Investment Banking, Jefferies

View the preliminary agenda: http://bit.ly/4nppSnt

Registration is Open

Save your complimentary tickets now. The afternoon and evening program will feature three keynote speeches from renowned CGT experts, four in-depth panel discussions featuring 20 distinguished speakers addressing core industry challenges, and will conclude with a reception designed to foster meaningful dialogue and connections.

Date: Thursday, November 20, 2025
Location: 116 Pall Mall, London, UK

RSVP: http://bit.ly/467jaet
(Register with code GSGM3 to claim a complimentary ticket — limited to the first 20 registrants)

LOS ANGELES, Oct. 20, 2025 /PRNewswire/ — Siipet, a growing pet tech startup, today announced the launch of LitterLens, the world’s first AI-powered health monitor designed specifically for feline litter box behavior. Now available on Siipet’s official website and Amazon at a retail price of $129 USD, LitterLens enables cat owners to track their pets’ bathroom frequency, duration, and overall habits, helping them detect early health changes and care with confidence.

“Changes in litter box habits are often among the first signs of urinary or digestive issues, yet they can easily go unnoticed, especially in multi-cat homes,” said Brian Fu, founder of Siipet. “With LitterLens, we make those hidden signals visible through accessible, AI-powered insights, helping cat parents take action early and protect their cats’ well-being.”

Smart Monitoring for Early Detection

LitterLens uses AI-driven analysis to monitor every litter box visit with precision, tracking frequency, duration, and stool conditions in real time. The CatSense+ detection system minimizes false alerts by accurately identifying each entry, ensuring users receive only relevant health insights. With instant in-app notifications, cat owners can act early to address potential urinary or digestive issues before they become serious.

Individualized Insights for Multi-Cat Homes

Powered by Pet ID+ technology, LitterLens distinguishes between multiple cats in a household through advanced visual recognition, allowing each pet’s data to be tracked and analyzed individually. This feature makes health monitoring more reliable for multi-cat families, where subtle changes are often difficult to notice.

Vet-Ready Records with Privacy Control

Through its PoopSnap function, LitterLens can automatically capture clear, time-stamped photos of irregular stools to support veterinary consultations and long-term health tracking. Data is stored securely in the Siipet app, where owners can review each cat’s trends and share updates with family members or veterinarians. For peace of mind, the Privacy Mode allows users to disable the camera at any time, while CatSense+ activates recording only when necessary.

Designed for Simplicity and Everyday Use

LitterLens is also built for convenience and durability, with a universal mounting system that fits most litter boxes and an IP65 water-resistant design for easy cleaning. The device provides HD live video with a built-in night light, runs on both wired and wireless power, and offers up to one month of battery life per charge.

Siipet is committed to making pet care more scientific, longer-lasting, and worry-free. As a global innovator in AI-driven pet health management, the brand aims to create tools that help pet owners understand their pets better, from tracking daily habits to spotting early signs of health issues. With products like the PawTrack Camera and newly launched LitterLens, Siipet turns everyday moments into meaningful data, empowering people to care for their pets with confidence and build a stronger, more connected bond with pets as family.

For more information, please visit: www.siipet.com

HANGZHOU, China, Oct. 20, 2025 /PRNewswire/ — Jiuzi Holdings, Inc. (NASDAQ: JZXN; the “Company”) today formally announced it has signed a Strategic Cooperation Agreement with leading Bitcoin fintech platform BitFi. Specializing in multi-chain staking and yield generation for BTC, BitFi delivers targeted, auditable Bitcoin income solutions for institutions and high-net-worth investors through integrated asset wrapping (wrapped BTC), cross-chain arbitrage, and hybrid strategy portfolios. Currently managing approximately US$2.75 billion in total value locked (TVL) across major chains including BSC (BTCB) and Ethereum (WBTC), BitFi continues expanding its ecosystem of wrapped BTC assets and interoperability protocols. This collaboration marks deep synergy between both parties within the Bitcoin ecosystem, aiming to propel digital asset financial innovation into a new phase.

Key Provisions of the Agreement

Phased Capital Injection & Scalable Synergy: Per the framework agreement, the Company will initiate cooperation by investing initial crypto assets, followed by planned progressive scaling of funds. It will gain full access to BitFi’s US$2.75B asset pool. This mechanism optimizes capital allocation efficiency while enabling robust growth under dynamic risk-balancing strategies.

Joint Governance & Product Innovation Committee: A special task force comprising executives and technical experts from both sides will focus on integrating cross-chain liquidity, developing structured yield products, and advancing compliant tokenization initiatives—such as derivative designs based on wrapped BTC and use cases combining real-world assets with on-chain financial instruments.

This strategic alignment underscores JZXN’s commitment to transforming into an integrated Bitcoin financial services provider. Leveraging BitFi’s proven expertise in multi-chain asset management and yield optimization, the Company plans to establish transparent, auditable, and SEC-compliant BTC exposure channels that empower shareholders to capture on-chain financial opportunities. Both parties emphasize strict adherence to Nasdaq listing rules and U.S. securities regulations to ensure governance compliance and operational security.

Li Tao, CEO of JZXN, stated: “Partnering with BitFi represents a critical step in our Web3 infrastructure deployment. By tapping into their global BTC liquidity network, we bridge traditional finance rigor with blockchain innovation vitality to create differentiated value for clients.”

About Jiuzi Holdings, Inc.

Jiuzi Holdings, Inc. is a leading provider of intelligent charging infrastructure for new energy vehicles in China’s third- and fourth-tier cities. The company focuses on high-power DC fast charging stations integrated with energy storage capabilities. For more information, please visit jzxn.com.

Presentations highlight HCB101’s differentiated profile and introduce first preclinical data from HCB301, underscoring HanchorBio’s innovation in next-generation immunotherapies

TAIPEI, SHANGHAI and SAN FRANCISCO, Oct. 20, 2025 /PRNewswire/ — HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies, today announced that new clinical data from HCB101, its differentiated, engineered SIRPα-Fc fusion protein, and the preclinical results from HCB301, its next-generation tri-specific checkpoint immunotherapy, will be presented at five major international oncology congresses in the fourth quarter of 2025.

The upcoming presentations will showcase progress from HCB101, including both the HCB101-101 monotherapy (NCT05892718) and the HCB101-201 combination (NCT06771622) studies, as well as the preclinical data from HCB301, underscoring the company’s innovation in advancing next-generation innate immune checkpoint therapies.

• Federation of Asian Clinical Oncology (FACO), October 24-25, 2025
  – Two poster presentations on HCB101 monotherapy and HCB101 in combination with standard of care in advanced cancers  
• Society for Immunotherapy of Cancer (SITC), November 5-9, 2025
  – Two late-breaking poster presentations from HCB101-101 and HCB101-201, highlighting safety, pharmacology, and emerging efficacy signals  
  – One poster presentation from HCB301, revealing the first-time the preclinical data from HanchorBio’s novel tri-specific fusion protein targeting CD47-SIRPα, PD-1, and TGFb pathways
• ESMO Asia Congress, December 5-7, 2025
  – One abstract updating the results from HCB101-101, demonstrating safety and activity across solid tumors and hematologic malignancies
• American Society of Hematology (ASH) Annual Meeting, December 6-9, 2025
  – Poster presentation of the first-in-human Phase 1 study of HCB101 in relapsed/refractory non-Hodgkin lymphoma
• ESMO Immuno-Oncology Congress (ESMO-IO), December 10-12, 2025
  – One abstract integrating the HCB101 monotherapy and combination data across multiple solid tumor indications

“Presenting across five major oncology meetings in one quarter underscores both the breadth and pace of HCB101’s clinical progress,” said Scott Liu, Ph.D., Chairman, CEO, and Founder of HanchorBio. “HCB101 continues to validate our differentiated approach to CD47-SIRPα blockade, while the first preclinical data from HCB301 showcase the innovation of our FBDB™ platform in advancing next-generation, multi-checkpoint therapies. Together, they highlight HanchorBio’s commitment to delivering transformative treatments for patients with difficult-to-treat cancers and advancing the next generation of immunotherapies.”

About HCB101: A Differentiated CD47-SIRPα Blockade
HCB101 is a 3.5^th-generation, affinity-optimized SIRPα-Fc fusion protein with an intact IgG4 Fc backbone, developed using HanchorBio’s proprietary FBDB™ platform. It is engineered for selective CD47 targeting with low red blood cell (RBC) binding, thereby avoiding the anemia and thrombocytopenia commonly associated with earlier anti-CD47 monoclonal antibodies, while preserving strong antibody-dependent cellular phagocytosis (ADCP) and innate-to-adaptive immune bridging.

Key Differentiators of HCB101:

• Enhanced safety: Demonstrates a cytopenia-sparing profile, with no dose-limiting toxicities observed up to 24 mg/kg and receptor occupancy >90% at ≥1.28 mg/kg, supporting a broad therapeutic window.
• Robust immune activation: Engineered to enhance ADCP and bridge innate-to-adaptive immunity, with evidence of durable immune-mediated tumor control in monotherapy.
• Broad tumor applicability: Demonstrated activity across >80 PDX and CDX preclinical models, with early clinical signals in gastric cancer, triple-negative breast cancer, head and neck squamous cell carcinoma, non-Hodgkin lymphoma, and ovarian cancer.
• Clinical translation: Shows durable disease control as monotherapy and a 100% confirmed partial response rate (6/6) in second-line gastric cancer when combined with ramucirumab and paclitaxel, with additional confirmed responses in first-line TNBC and second-line HNSCC, substantially exceeding historical benchmarks.

About HCB301: a Tri-Specific Checkpoint Immunotherapy
HCB301 is HanchorBio’s next-generation immunotherapy designed to integrate three synergistic mechanisms into a single molecule: CD47-SIRPα blockade to activate macrophage-mediated phagocytosis, PD-1 inhibition to restore exhausted T cells, and TGF-b pathway suppression to improve tumor micro-environment. Developed using the proprietary FBDB™ platform, HCB301 represents a next-generation approach to multi-checkpoint immunotherapy. Preclinical studies demonstrated enhanced immune activation and potent antitumor activities, and the first results will be presented at SITC 2025.

About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (7827.TPEx), a global biotechnology company specializing in immuno-oncology, is led by an experienced team of pharmaceutical industry veterans with a proven track record of success in biologics discovery and global development, aiming to rewrite cancer therapies. Committed to reactivating the immune system to fight diseases, the proprietary Fc-based designer biologics (FBDB™) platform enables the development of unique biologics with diverse multi-targeting modalities, unleashing both innate and adaptive immunity to overcome the current challenges of anti-PD1/L1 therapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By making breakthroughs in multi-functional innovative molecular configurations in R&D and improving the manufacturing process in CMC, HanchorBio develops transformative medicines to address unmet medical needs. For more information, please visit: www.HanchorBio.com